EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Medeze Group PCL (MEDEZE) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Medeze Group PCL THB 1.91, price THB 6.10, upside -68.7%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TH

MG Thin data Sep 24, 2026

Medeze Group PCL

MEDEZE · BK

Weakest SetupStrongly overvalued and low quality.

!Fair value 1.91 THB · Strongly overvalued (−69%)
!Quality 45/100
!Weak Growth (revenue YoY −10.3 %/yr)
✓Highly profitable · 21.2% net margin (TTM)
!negative free cash flow
·2.62% dividend yield
!Trails peers (3/12)
!Moderate moat 64/100
!Evidence only low, so the estimate is less certain
!Weak on past: 21 out of 100
Watch Medeze Group PCL for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

11.63 THB 5.97 THB Fair Value 1.91 THB Oct 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

23‑month range 5.97 THB – 11.63 THB · fair‑value band 1.89 THB – 1.91 THB · the 6.10 THB price screens above the 1.91 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Medeze Group PCL in your weekly email

Every Wednesday you see whether Medeze Group PCL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products.

Show more

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells. In addition, the company is involved in research, develops, and collects data on all types of human cellular activities and medical laboratory tests. Further, the company sells dietary supplements, cosmetics, and dermo cosmetics. Medeze Group Public Company Limited was founded in 2010 and is based in Nakhon Pathom, Thailand.

Stock analysis

Medeze Group PCL (MEDEZE) currently trades at 6.10 THB, while our model-based Fair Value estimate is 1.91 THB, implying the stock looks roughly 219.4% overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 3.27 THB per share, and 0 of the 15 models we run sit above the 6.10 THB price.

Bear case: the Dividend Discount group reads lowest at 1.19 THB, and 15 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: 1.89 THB (bear) to 1.91 THB (bull), the price of 6.10 THB sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Medeze Group PCL reported revenue of 744M THB in FY2025 versus 702M THB in FY2023, a compound +2.9%/yr. Reported net income was 196M THB in FY2025, compounding −9.5%/yr from FY2023.

Key figures

Market cap 7.0B THB (≈ $211M) · P/E ratio 43.6 · P/S ratio 11.5 · EPS (TTM) 0.1400 THB · Dividend yield 2.6% · Net margin 26.4% · Return on equity 5.2% · Return on assets (EBIT) 15.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 15% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −69%, MEDEZE screens richer than that median.

Fair Value models

Bear 1.89 THB Fair Value 1.91 THB Bull 1.91 THB
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income 2.01 THB 2.05 THB 1.96 THB 69
Owner Earnings 1.63 THB 1.74 THB 1.93 THB 68
EPV 2.38 THB 2.53 THB 2.65 THB 68
All 15 models by family
DCF Models
Owner Earnings 1.63 THB 1.74 THB 1.93 THB 68
Earnings-Based
Graham-Dodd 1.25 THB 1.53 THB 1.72 THB 61
EPV 2.38 THB 2.53 THB 2.65 THB 68
Dividend Discount
Gordon GGM 1.11 THB 1.19 THB 1.30 THB 63
DDM Multi-Stage 1.11 THB 1.29 THB 1.51 THB 61
Multiples
P/E Multiple 3.03 THB 4.05 THB 5.06 THB 63
P/S Multiple 1.83 THB 2.44 THB 3.05 THB 58
P/B Multiple 2.34 THB 3.13 THB 3.91 THB 55
EV/EBIT 3.90 THB 4.81 THB 5.72 THB 63
EV/EBITDA 3.79 THB 4.66 THB 5.52 THB 64
EV/Revenue 2.64 THB 3.27 THB 3.89 THB 52
Asset-Based
NCAV (Graham) 1.36 THB 1.83 THB 2.73 THB 51
Economic Profit
Residual Income 2.01 THB 2.05 THB 1.96 THB 69
ROIC Compounder 2.38 THB 2.53 THB 2.65 THB 64
Growth Earnings
Growth-Adj P/E 2.14 THB 3.06 THB 3.97 THB 61

Open the full fair value analysis →

Notify me when MEDEZE reaches fair value

Put MEDEZE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 45/100

Of which business quality 47 · Market factors (momentum, volatility) 38

Profitability 43
Margins and returns on capital today
Quality Growth 12
Are margins and returns improving?
Cashflow 28
Earnings quality: real cash, not paper profit
Fin. Strength 97
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 65
Calm price path (market factor)
Momentum 34
Price trend over the last 3–12 months (market factor)
52W Momentum 15
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 13/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

MEDEZE screens 219% overvalued. Compare with HCA Healthcare, Inc →

Compare Medeze Group PCL with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks

Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −69% · Bottom 25%
Profitability
Return on equity (TTM) 5% · Below median
Return on assets 3% · Below median
Net margin (TTM) 21% · Top 25%
Operating margin (TTM) 30% · Top 25%
Growth and dividend
Revenue growth −19% · Bottom 25%
Dividend yield (TTM) 2.6% · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 43.6× · Priciest 25%
P/B 2.42× · Pricier than median
P/S (TTM) 9.58× · Priciest 25%
EV/EBITDA 26.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)21 · sector 31
HEALTH (low debt)0 · sector 89
DIVIDEND (yield)52 · sector 43

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $436.48 $592.64 +36%
Fresenius SE FRE €45.74 €34.54 −24%
Dr. Sulaiman Al Habib Medical Services Group 4013 227.50 SAR 109.45 SAR −52%
IHH Healthcare Berhad, an investment holding company, 5225 8.00 MYR 4.87 MYR −39%
Tenet Healthcare Corporation THC $256.44 $399.58 +56%
DaVita Inc DVA $183.14 $255.97 +40%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹9,069 ₹2,908 −68%
Fresenius Medical Care AG FMS $22.41 $45.58 +103%
Aier Eye Hospital Group 300015 ¥8.07 ¥10.86 +35%
Encompass Health Corporation EHC $122.76 $96.51 −21%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medeze Group PCL · Fair Value
1.91 THB −219%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Medeze Group PCL Fair Value". https://www.fairvalue-calculator.com/stock/MEDEZE

Frequently asked questions

Is Medeze Group PCL (MEDEZE) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1.91 THB versus a price of 6.10 THB, about −69% upside (overvalued).
What is the fair value of MEDEZE?
Our model-based fair value for Medeze Group PCL is 1.91 THB (as of Sep 24, 2026), built from audited fundamentals. The current price: 6.10 THB.
What is the quality score of MEDEZE?
Medeze Group PCL has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medeze Group PCL (MEDEZE)?
Our model-based price target is the fair value of 1.91 THB (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 1.89 THB, optimistic scenario 1.91 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Medeze Group PCL stock forecast for 2026?
Our models put fair value at 1.91 THB, about −69% upside versus a price of 6.10 THB (overvalued). Cautious scenario 1.89 THB, optimistic scenario 1.91 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Medeze Group PCL (MEDEZE)?
Medeze Group PCL reported trailing-twelve-month revenue of about 736M THB (latest available figure, as of Sep 24, 2026).
Does Medeze Group PCL pay a dividend?
Medeze Group PCL currently shows a dividend yield of about 2.62% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Medeze Group PCL (MEDEZE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medeze Group PCL it is 1.91 THB per share (as of Sep 24, 2026), against a price of 6.10 THB. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Medeze Group PCL stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MEDEZE trades above its calculated fair value: price 6.10 THB, fair value 1.91 THB, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDEZE?
No. The price is what the market pays today (6.10 THB); the fair value is what the company's own numbers justify (1.91 THB). For Medeze Group PCL the two are 4.19 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Medeze Group PCL worth?
The market values Medeze Group PCL at about 7.0B THB (market capitalisation, as of Sep 24, 2026). Per share that is 6.10 THB; our models calculate a fair value of 1.91 THB per share.
What do the bullish and bearish scenarios say about MEDEZE?
Our models span a range for Medeze Group PCL: cautious scenario 1.89 THB, base 1.91 THB, optimistic 1.91 THB per share (as of Sep 24, 2026, price 6.10 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDEZE?
Medeze Group PCL trades at a price-to-earnings ratio of 43.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.91 THB is built from several models across several years. Other multiples: P/B 2.4, P/S 9.6, EV/EBITDA 26.1.
How solid is the balance sheet of Medeze Group PCL (MEDEZE)?
Balance-sheet figures for Medeze Group PCL (as of Sep 24, 2026): return on equity 5.2%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is MEDEZE from its 52-week high?
Medeze Group PCL trades at 6.10 THB, about 15% below its 52-week high of 7.21 THB and 2% above the low of 5.97 THB (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1.91 THB is for.
Which stocks are comparable to Medeze Group PCL?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medeze Group PCL stock attractive at the current price?
The data as of Sep 24, 2026: price 6.10 THB, calculated fair value 1.91 THB (−69%), Quality Score 45/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDEZE calculated?
We run Medeze Group PCL through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.91 THB, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Medeze Group PCL itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medeze Group PCL (MEDEZE)?
The closing price on Sep 24, 2026 was 6.10 THB. Our model-based fair value is 1.91 THB, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medeze Group PCL right now?
The price sits above even our optimistic bull case (1.91 THB). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (1.89 THB to 1.91 THB), unusually little disagreement for a valuation.

Key figures of Medeze Group PCL

How large is the market capitalisation of Medeze Group PCL (MEDEZE)?
The market capitalisation of Medeze Group PCL is 7.0B THB (≈ $211M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medeze Group PCL (MEDEZE)?
The price-to-sales ratio of Medeze Group PCL is 11.5 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medeze Group PCL (MEDEZE)?
Earnings per share at Medeze Group PCL are 0.1400 THB (price ÷ EPS = P/E 43.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Medeze Group PCL (MEDEZE)?
The dividend yield of Medeze Group PCL is 2.6% (payout 114%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Medeze Group PCL (MEDEZE)?
The net margin of Medeze Group PCL is 26.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medeze Group PCL (MEDEZE)?
The return on equity (ROE) of Medeze Group PCL is 5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medeze Group PCL (MEDEZE)?
On an EBIT basis the return on assets of Medeze Group PCL is 15.7% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medeze Group PCL (MEDEZE)?
The operating margin of Medeze Group PCL is 30.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medeze Group PCL (MEDEZE)?
Revenue at Medeze Group PCL is growing −18.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medeze Group PCL (MEDEZE)?
Earnings per share at Medeze Group PCL are growing −54.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medeze Group PCL (MEDEZE) generate?
The free cash flow of Medeze Group PCL is −17.1M THB (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Medeze Group PCL in the live analysis

One click puts Medeze Group PCL on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.